Haydeh Payami

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1956997/publications.pdf

Version: 2024-02-01

71 papers	9,571 citations	76326 40 h-index	79698 73 g-index
79 all docs	79 docs citations	79 times ranked	12482 citing authors

#	Article	IF	Citations
1	Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nature Genetics, 2014, 46, 989-993.	21.4	1,685
2	Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nature Genetics, 2010, 42, 781-785.	21.4	692
3	Large-scale association analyses identify host factors influencing human gut microbiome composition. Nature Genetics, 2021, 53, 156-165.	21.4	676
4	Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome. Movement Disorders, 2017, 32, 739-749.	3.9	649
5	Identification of a Novel LRRK2 Mutation Linked to Autosomal Dominant Parkinsonism: Evidence of a Common Founder across European Populations. American Journal of Human Genetics, 2005, 76, 672-680.	6.2	524
6	Comprehensive Research Synopsis and Systematic Meta-Analyses in Parkinson's Disease Genetics: The PDGene Database. PLoS Genetics, 2012, 8, e1002548.	3.5	495
7	Independent Predictors of Cognitive Decline in Healthy Elderly Persons. Archives of Neurology, 2002, 59, 601.	4.5	300
8	The Number of Trait Loci in Late-Onset Alzheimer Disease. American Journal of Human Genetics, 2000, 66, 196-204.	6.2	286
9	Functional variants in the LRRK2 gene confer shared effects on risk for Crohnâ€™s disease and Parkinsonâ€™s disease. Science Translational Medicine, 2018, 10, .	12.4	273
10	Metaâ€analysis of Parkinson's Disease: Identification of a novel locus, RIT2. Annals of Neurology, 2012, 71, 370-384.	5.3	264
11	Increased risk of Parkinson's disease in parents and siblings of patients. Annals of Neurology, 1994, 36, 659-661.	5.3	214
12	Genome-Wide Gene-Environment Study Identifies Glutamate Receptor Gene GRIN2A as a Parkinson's Disease Modifier Gene via Interaction with Coffee. PLoS Genetics, 2011, 7, e1002237.	3.5	206
13	Cognitive Markers Preceding Alzheimer's Dementia in the Healthy Oldest Old. Journal of the American Geriatrics Society, 1997, 45, 584-589.	2.6	172
14	SNCA Variant Associated With Parkinson Disease and Plasma Î±-Synuclein Level. Archives of Neurology, 2010, 67, 1350-6.	4.5	157
15	Association of Parkinson Disease with Structural and Regulatory Variants in the HLA Region. American Journal of Human Genetics, 2013, 93, 984-993.	6.2	145
16	Frequency of Tau Gene Mutations in Familial and Sporadic Cases of Non-Alzheimer Dementia. Archives of Neurology, 2001, 58, 383-7.	4.5	143
17	Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens. Npj Parkinson's Disease, 2020, 6, 11.	5.3	140
18	Stool Immune Profiles Evince Gastrointestinal Inflammation in Parkinson's Disease. Movement Disorders, 2018, 33, 793-804.	3.9	130

#	Article	IF	Citations
19	Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's disease. Annals of Neurology, 2007, 62, 137-144.	5.3	129
20	Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk. Movement Disorders, 2008, 23, 88-95.	3.9	129
21	LRRK2 G2019S in Families with Parkinson Disease Who Originated from Europe and the Middle East: Evidence of Two Distinct Founding Events Beginning Two Millennia Ago. American Journal of Human Genetics, 2006, 79, 752-758.	6.2	111
22	Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease. Movement Disorders, 2010, 25, 2156-2163.	3.9	108
23	Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patients. Annals of Neurology, 2007, 61, 47-54.	5.3	105
24	SCA2 may present as levodopa-responsive parkinsonism. Movement Disorders, 2003, 18, 425-429.	3.9	99
25	Exploring gene-environment interactions in Parkinsonâ€™s disease. Human Genetics, 2008, 123, 257-265.	3.8	92
26	Evidence for a Novel Late-Onset Alzheimer Disease Locus on Chromosome 19p13.2. American Journal of Human Genetics, 2004, 75, 398-409.	6.2	90
27	Postural instability/gait disturbance in Parkinson's disease has distinct subtypes: an exploratory analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 564-568.	1.9	90
28	Parkinson's disease andLRRK2: Frequency of a common mutation in U.S. movement disorder clinics. Movement Disorders, 2006, 21, 519-523.	3.9	84
29	Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international study. Lancet Neurology, The, 2006, 5, 917-923.	10.2	83
30	Familial Aggregation of Parkinson Disease. Archives of Neurology, 2002, 59, 848-50.	4.5	75
31	The heritability of risk and age at onset of Parkinson's disease after accounting for known genetic risk factors. Journal of Human Genetics, 2010, 55, 241-243.	2.3	70
32	Early-Onset Alzheimer Disease in Families With Late-Onset Alzheimer Disease. Archives of Neurology, 2006, 63, 1307.	4.5	62
33	Diseaseâ€related and genetic correlates of psychotic symptoms in Parkinson's disease. Movement Disorders, 2011, 26, 2190-2195.	3.9	61
34	Genetic association between Î±â€synuclein and idiopathic parkinson's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 1222-1230.	1.7	60
35	Evidence for More than One Parkinson's Disease-Associated Variant within the HLA Region. PLoS ONE, 2011, 6, e27109.	2.5	60
36	Analysis of the Î±-synuclein G209A mutation in familial Parkinson's disease. Lancet, The, 1998, 351, 37-38.	13.7	55

#	Article	IF	Citations
37	Identification of a novel Parkinsonâ€™s disease locus via stratified genome-wide association study. BMC Genomics, 2014, 15, 118.	2.8	53
38	Modulation of the age at onset of Parkinson's disease by apolipoprotein E genotypes. Annals of Neurology, 1997, 42, 655-658.	5.3	52
39	parkin mutation analysis in clinic patients with early-onset Parkinson's disease. American Journal of Medical Genetics Part A, 2004, 129A, 44-50.	2.4	49
40	Cognitive and Motor Function in Long-DurationPARKIN-Associated Parkinson Disease. JAMA Neurology, 2014, 71, 62.	9.0	49
41	Identification of genetic modifiers of age-at-onset for familial Parkinsonâ€™s disease. Human Molecular Genetics, 2016, 25, 3849-3862.	2.9	44
42	The emerging science of precision medicine and pharmacogenomics for Parkinson's disease. Movement Disorders, 2017, 32, 1139-1146.	3.9	42
43	Genetic Epidemiology of Parkinson's Disease. Journal of Geriatric Psychiatry and Neurology, 1998, 11, 98-106.	2.3	38
44	Leucine-rich repeat kinase 1: a paralog of LRRK2 and a candidate gene for Parkinsonâ€™s disease. Neurogenetics, 2007, 8, 95-102.	1.4	34
45	Validity and Utility of a LRRK2 G2019S Mutation Test for the Diagnosis of Parkinson's Disease. Genetic Testing and Molecular Biomarkers, 2006, 10, 221-227.	1.7	32
46	Genomewide Association Studies of <scp>LRRK2</scp> Modifiers of Parkinson's Disease. Annals of Neurology, 2021, 90, 76-88.	5.3	30
47	False-positive SCA8 gene test in a patient with pathologically proven multiple system atrophy. Annals of Neurology, 2005, 57, 462-463.	5.3	29
48	Apolipoprotein E genotype does not affect the age of onset of dementia in families with defined tau mutations. Neuroscience Letters, 1999, 260, 193-195.	2.1	27
49	Evidence of linkage and association on chromosome 20 for late-onset Alzheimer disease. Neurogenetics, 2004, 5, 121-128.	1.4	27
50	Expression of Î±-synuclein in the human brain: relation to Lewy body disease. Molecular Brain Research, 2001, 92, 58-65.	2.3	26
51	Using global team science to identify genetic parkinson's disease worldwide. Annals of Neurology, 2019, 86, 153-157.	5.3	26
52	One step closer to fixing association studies: evidence for age- and gender-specific allele frequency variations and deviations from Hardy-Weinberg expectations in controls. Human Genetics, 2005, 118, 322-330.	3.8	25
53	Lack of evidence for an association between UCHL1 S18Y and Parkinsonâ€™s disease. European Journal of Neurology, 2008, 15, 134-139.	3.3	25
54	Caffeine, creatine, GRIN2A and Parkinson's disease progression. Journal of the Neurological Sciences, 2017, 375, 355-359.	0.6	23

#	Article	IF	Citations
55	Analysis of the LRRK2 G2019S Mutation in Alzheimer Disease. Archives of Neurology, 2006, 63, 156.	4.5	21
56	Segregation analysis of Parkinson disease. , 1998, 80, 410-417.		19
57	Accurate Determination of Ataxin-2 Polyglutamine Expansion in Patients with Intermediate-Range Repeats. Genetic Testing and Molecular Biomarkers, 2002, 6, 217-220.	1.7	18
58	The relationship between obsessiveâ€compulsive symptoms and PARKIN genotype: The COREâ€PD study. Movement Disorders, 2015, 30, 278-283.	3.9	16
59	Exploring human-genome gut-microbiome interaction in Parkinsonâ€™s disease. Npj Parkinson's Disease, 2021, 7, 74.	5.3	15
60	A linkage study of candidate loci in familial Parkinson's Disease. BMC Neurology, 2003, 3, 6.	1.8	14
61	Promise of Pharmacogenomics for Drug Discovery, Treatment and Prevention of Parkinson's Disease. A Perspective. Neurotherapeutics, 2014, 11, 111-116.	4.4	14
62	Plasticity-related gene 3 (LPPR1) and age at diagnosis of Parkinson disease. Neurology: Genetics, 2018, 4, e271.	1.9	12
63	DNA variants in CACNA1C modify Parkinson disease risk only when vitamin D level is deficient. Neurology: Genetics, 2016, 2, e72.	1.9	11
64	parkinmutation dosage and the phenomenon of anticipation: a molecular genetic study of familial parkinsonism. BMC Neurology, 2005, 5, 4.	1.8	10
65	Lack of evidence for maternal effect in familial Alzheimer's disease. Genetic Epidemiology, 1993, 10, 461-464.	1.3	9
66	Apolipoprotein EÂÎµ4 Is Associated with Neuronal Loss in the Substantia nigra in Alzheimerâ€™s Disease. Dementia and Geriatric Cognitive Disorders, 1999, 10, 437-441.	1.5	8
67	DBH â^'1021Câ†'T does not modify risk or age at onset in Parkinson's disease. Annals of Neurology, 2007, 62, 99-101.	5.3	7
68	Glutamate Receptor Gene GRIN2A, Coffee, and Parkinson Disease. PLoS Genetics, 2014, 10, e1004774.	3.5	7
69	Visualizing disease associations: graphic analysis of frequency distributions as a function of age using moving average plots (MAP) with application to Alzheimer's and Parkinson's disease. Genetic Epidemiology, 2010, 34, 92-99.	1.3	6
70	Exclusion of dominant mutations within the FTDP-17 locus on chromosome 17 for Parkinson's disease. Neuroscience Letters, 1999, 272, 140-142.	2.1	4
71	Reply to correspondence from Inzelberg et al.??onset age of Parkinson disease?. American Journal of Medical Genetics Part A, 2002, 111, 461-461.	2.4	1